Long-Term Intrapatient Evolution During HIV-2 Infection

HIV-2 disease progression and transmission is attenuated compared to HIV-1, yet prospective studies examining HIV-2 intrapatient evolution have been limited. We examined viral sequence evolution in the C2V3C3 region of the viral env gene in 8 HIV-2 infected individuals from Dakar, Senegal, over the course of approximately 10 years. To compare results to HIV-1 infection, we reanalyzed data from our previous study that examined intrapatient evolution in HIV-1 infected individuals from the same population. HIV-2 sequences from early and late timepoints were phylogenetically intermixed for all subjects, and no distinct trends were observed in terms of increases or decreases in fragment size or number of N-linked glycosylation sites. In homologous env C2V3 sequence, rates of viral divergence and diversification were slower in individuals infected with HIV-2 than individuals with HIV-1. This data indicates that viral evolution occurs slowly in HIV-2 infection, which is consistent with the slow disease progression observed in HIV-2 infection, and supports the notion that viral evolution may be a relevant correlate for disease progression

Genomic Sites of Human Immunodeficiency Virus Type 2 (HIV-2) Integration: Similarities to HIV-1 In Vitro and Possible Differences In Vivo

Retroviruses have distinct preferences in integration site selection in the host cell genome during in vitro infection, with human immunodeficiency virus type 1 (HIV-1) integration strongly favoring transcriptional units. Additionally, studies with HIV-1 have shown that the genomic site of proviral integration may impact viral replication, with integration in heterochromatin associated with a block in viral transcription. HIV-2 is less pathogenic than HIV-1 and is believed to have a lower replication rate in vivo. Although differences in integration site selection between HIV-2 and HIV-1 could potentially explain the attenuated pathogenicity of HIV-2, no studies have characterized integration site selection by HIV-2. In this study, we mapped 202 HIV-2 integration sites during in vitro infection of peripheral blood mononuclear cells with a primary HIV-2 isolate. In addition, we assayed for in vivo proviral integration within heterochromatin in 21 HIV-1-infected subjects and 23 HIV-2-infected subjects, using an alphoid repeat PCR assay. During in vitro infection, HIV-2 displayed integration site preferences similar to those previously reported for HIV-1. Notably, 82% of HIV-2 integrations mapped to Refseq genes, and integration strongly favored regions of the genome with high gene density and high GC content. Though rare, the proportion of HIV-2 subjects with evidence of proviral integration within heterochromatin in vivo was higher than that of HIV-1-infected subjects. It is therefore possible that integration site selection may play a role in the differences in HIV-1 and HIV-2 in vivo pathogenesis

The Level of APOBEC3G (hA3G)-Related G-to-A Mutations Does Not Correlate with Viral Load in HIV Type 1-Infected Individuals

The APOBEC family of mammalian cytidine deaminases, such as APOBEC3G (hA3G), has been demonstrated to function as a host viral restriction factor against HIV-1. hA3G has been shown to cause extensive G-to-A mutations in the HIV-1 genome, which may play a role in viral restriction. To investigate the role of G-to-A mutations in HIV-1 pathogenesis, we isolated, amplified, and sequenced HIV-1 sequences (vif, gag, and env) from 29 therapy-naive HIV-1-infected individuals. The levels of G-to-A mutations correlated with the expression levels of hA3G in the vif (rho = 0.438, p = 0.041) and the env regions (rho = 0.392, p = 0.038), but not in the gag region (rho = 0.131, p = 0.582). There is no correlation between viral load and the level of G-to-A mutations in the vif (rho = 0.144, p = 0.522), env (rho = 0.168, p = 0.391), or gag regions (rho = −0.254, p = 0.279). Taken together, these findings suggest that the hA3G-induced G-to-A mutations may not be the mechanism by which hA3G restricts or controls viral replication. Thus, hA3G might be restricting viral growth in infected individuals through a mechanism that is independent of the cytidine deaminase activities of hA3G

Direct Evidence of Lower Viral Replication Rates In Vivo in Human Immunodeficiency Virus Type 2 (HIV-2) Infection than in HIV-1 Infection▿

Studies have shown that human immunodeficiency virus type 2 (HIV-2) is less pathogenic than HIV-1, with a lower rate of disease progression. Similarly, plasma viral loads are lower in HIV-2 infection, suggesting that HIV-2 replication is restricted in vivo in comparison to that of HIV-1. However, to date, in vivo studies characterizing replication intermediates in the viral life cycle of HIV-2 have been limited. In order to test the hypothesis that HIV-2 has a lower replication rate in vivo than HIV-1 does, we quantified total viral DNA, integrated proviral DNA, cell-associated viral mRNA, and plasma viral loads in peripheral blood samples from groups of therapy-naïve HIV-1-infected (n = 21) and HIV-2-infected (n = 18) individuals from Dakar, Senegal, with CD4+ T-cell counts of >200/μl. Consistent with our previous findings, total viral DNA loads were similar between HIV-1 and HIV-2 and plasma viral loads were higher among HIV-1-infected individuals. Proportions of DNA in the integrated form were also similar between these viruses. In contrast, levels of viral mRNA were lower in HIV-2 infection. Our study indicates that HIV-2 is able to establish a stable, integrated proviral infection in vivo, but that accumulation of viral mRNA is attenuated in HIV-2 infection relative to that in HIV-1 infection. The differences in viral mRNA are consistent with the differences in plasma viral loads between HIV-1 and HIV-2 and suggest that lower plasma viral loads, and possibly the attenuated pathogenesis of HIV-2, can be explained by lower rates of viral replication in vivo

Caractérisation phytochimique et étude de l’activité antimicrobienne d’extraits de feuilles de trois plantes de la flore sénégalaise : Detarium senegalense, Detarium microcarpum et Piliostigma reticulatum

Detarium senegalense, Detarium microcarpum et Piliostigma reticulatum sont trois plantes de la flore sénégalaise, utilisées en médecine traditionnelle pour la prise en charge de maladies infectieuses. Cette étude visait à déterminer in vitro l’activité antimicrobienne d’extraits et de fractions de feuilles de ces plantes sur différentes souches (Escherichia coli, Klebsiella oxytoca, Pseudomonas aeruginosa, Enterococus faecalis, Staphylococcus aureus et Candida albicans). Les méthodes de diffusion en milieu solide et de dilution en milieu liquide ont été utilisées pour la détermination des Diamètres d’Inhibition (DI) et des Concentrations Minimales Inhibitrices (CMI). Le screening phytochimique a été réalisé par des tests de caractérisation reposant sur des réactions physico-chimiques et par chromatographie sur couche mince. Sur l’ensemble des échantillons testés, seule la fraction dichlorométhanique de P. reticulatum était inactive sur les souches bactériennes étudiées. Les DI variaient entre 10 et 23 mm pour les échantillons actifs. Les CMI étaient comprises entre 0,0293 et 2,50 mg/mL. Les fractions d’acétate d’éthyle étaient les plus actives. Les familles de molécules suivantes ont été identifiées : tanins, flavonoïdes et saponosides. Les teneurs en polyphénols totaux variaient de 0,66 à 19 mg équivalent acide tannique/g. Cette étude a montré que les extraits des trois plantes sont dotés d’un fort pouvoir antimicrobien et contiennent plusieurs familles de composés chimiques